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drug-eluting stent (DES) arms of the trials, avoiding inclusion of the
bare-metal stent (BMS) arms. Indeed, much of the visual assessment
of the relationships shown seems dependent on the BMS arms of the
trials included. We believe that the relationship between mean LL
and TLR rate is a crucial point in clinical practice to decide which
DES performs better and in the development of new DES to
understand whether a new device can compete with the ones already
on the market. Thus a more accurate and definitive analysis of this
correlation should be clearly made and should only include patients
treated with DES. In light of this, the authors correctly recognized
that, in the REALITY (Prospective Randomized Multi-Center
Head-to-Head Comparison of the Sirolimus-Eluting Stent [Cypher]
and the Paclitaxel-Eluting Stent [Taxus]) trial ( 2), which directly
compared 2 DES, the TLR rates were similar despite a highly
significant difference in LL and %DS. We suggest a possible expla-
nation for this apparent paradox. Bare metal stents have been shown
to have a bimodal distribution of angiographic measures of restenosis
(3). We have suggested that this distribution can be possible also with
DES (4,5). Sirolimus-eluting stents showed a sort of “all-or-none”
phenomenon, having a very low average LL driven by the lack of LL
in nonrestenotic lesions. Paclitaxel-eluting stents, in contrast, accom-
modated some LL also in nonrestenotic lesions and this led to a
higher average LL value.
We urge the authors to test again this hypothesis and to perform
a detailed analysis of the distribution of LL and %DS, given the large
database of prospectively enrolled patients with independently per-
formed quantitative coronary angiographic analysis that they can
access. If the bimodal distribution of angiographic parameters of
restenosis were confirmed also for DES, this could have a major
impact in the design, analysis, and conduct of future comparative
DES trials.
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Reply
We appreciate the insightful comments of Drs. Agostini and
Biondi-Zoccai about our study (1). Regarding their first point, we
felt it was relevant to concentrate on the direct comparisons of late
loss (LL) and percentage diameter stenosis (%DS) with target
lesion revascularization (TLR) in the same patients. We recognize
the potential impact of the oculostenotic reflex on risk of TLR, but
can confirm that the treatment differences in TLR in angiographic
and clinical cohorts were in fact similar in those large trials with
over 150 patients in both cohorts (DELIVER, ENDEAVOR II,
SIRIUS, and TAXUS IV). We have also previously reported that
in the TAXUS IV trial routine angiographic follow-up increased
TLR rates by approximately 40%, though to a similar degree with
bare-metal stents (BMS) and drug-eluting stents (DES) (2).
Regarding their second point, we distinguish between DES and
BMS arms in the visual plots of mean LL or %DS and TLR rates,
so readers can readily assess the association for DES arms alone. In
the 11 trials, the distributions of LL in both the DES and BMS
arms are not bimodal but somewhat skewed to the right.
That is why we propose the use of the predictive formulas in the
Appendix to work out what TLR rate one expects for a given DES,
given the observed distributions (rather than just the mean) of LL
or %DS.
We have an alternative explanation for the apparent paradox
whereby highly significant differences in LL and %DS for 2
different DES nevertheless lead to somewhat similar TLR rates.
The logistic curvilinear relation between TLR and LL means that
the majority of patients will have LL at the rather flat left-hand
end of the curve, and therefore there is little difference in risk of
TLR in such patients. Thus a highly significant difference in LL
between 2 stents but with typically low LL in most patients can be
expected to lead to a rather small (but real) difference in true TLR
rates. However, most trials are of insufficient size to distinguish
such small true differences from the null hypothesis of no differ-
ence. That is why we believe insight into vessel-related efficacy is
best done first with fairly small trials based on these surrogates, to
be followed by much larger simpler trials, without planned
follow-up angiograms, to evaluate patient-oriented stent safety.
Finally, we do believe that rare phenomena such as strut fracture
or hypersensitivity reactions may occasionally result in restenosis
unrelated to the logistic equations we have proposed. These,
however, are unusual occurrences, and as such LL and %DS may
be used as angiographic surrogates for the clinical event TLR.
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